Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H32N2O2 |
| Molecular Weight | 392.5338 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=INUNXTSAACVKJS-OAQYLSRUSA-N
InChI=1S/C25H32N2O2/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27/h2-7,10-13,21H,8-9,14-20H2,1H3/t21-/m1/s1
| Molecular Formula | C25H32N2O2 |
| Molecular Weight | 392.5338 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1959-01-01_4_page004.htmlCurator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=G7As-qawdzMC&printsec=frontcover&hl=ru#v=onepage&q&f=false | https://www.cbg-meb.nl/documenten/rapporten/2015/09/14/par-dextromoramide | https://medikamio.com/nl-nl/geneesmiddelen/palfium-tablet-5-mg/pil
Sources: https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1959-01-01_4_page004.html
Curator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=G7As-qawdzMC&printsec=frontcover&hl=ru#v=onepage&q&f=false | https://www.cbg-meb.nl/documenten/rapporten/2015/09/14/par-dextromoramide | https://medikamio.com/nl-nl/geneesmiddelen/palfium-tablet-5-mg/pil
Dextromoramide is a synthetic strong-acting opioid and full mu-opioid receptor agonist. Dextromoramide is a Schedule I drug illegal to possess. The current indication for Palfium® (dextromoramide) is severe acute or chronic pain requiring opioids, such as post-operative pain, and pain associated with bone fractures, malignancies and acute renal/biliary colic attacks in adults.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PALFIUM Approved UsePalfium® (dextromoramide) is a synthetic strong-acting opioid and full mu-opioid receptor agonist that has been registered in the Netherlands since 1974. The current indication is severe acute or chronic pain requiring opioids, such as post-operative pain, and pain associated with bone fractures, malignancies and acute renal/biliary colic attacks in adults. Launch Date1973 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2000 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8931067/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
40 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8931067/ |
5 mg single, sublingual dose: 5 mg route of administration: Sublingual experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
106 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2714730/ |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1775.4 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8931067/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
526 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8931067/ |
5 mg single, sublingual dose: 5 mg route of administration: Sublingual experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.81 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2714730/ |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.02 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8931067/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.37 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8931067/ |
5 mg single, sublingual dose: 5 mg route of administration: Sublingual experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2714730/ |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROMORAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg single, intravenous Accidental dose Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Other AEs: Death... |
40 mg 1 times / hour multiple, oral Highest recorded dose Dose: 40 mg, 1 times / hour Route: oral Route: multiple Dose: 40 mg, 1 times / hour Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Disc. AE: Drug abuse... AEs leading to discontinuation/dose reduction: Drug abuse Sources: |
20 mg single, rectal Highest studied dose |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Death | 100 mg single, intravenous Accidental dose Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Drug abuse | Disc. AE | 40 mg 1 times / hour multiple, oral Highest recorded dose Dose: 40 mg, 1 times / hour Route: oral Route: multiple Dose: 40 mg, 1 times / hour Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:21 GMT 2025
by
admin
on
Mon Mar 31 18:21:21 GMT 2025
|
| Record UNII |
9S4S6CIY83
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN02AC01
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
||
|
WHO-ATC |
N02AC01
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
||
|
DEA NO. |
9613
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
357-56-2
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
C87357
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
DTXSID8022909
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
m4228
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
3290
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
843
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
74274
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
9S4S6CIY83
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
206-613-1
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
92943
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
D003916
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
100000082898
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
SUB07052MIG
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
DEXTROMORAMIDE
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
733
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY | |||
|
DB01529
Created by
admin on Mon Mar 31 18:21:21 GMT 2025 , Edited by admin on Mon Mar 31 18:21:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER | |||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
(+)-4-[2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl]morpholine
(A dextro-rotatory isomer of moramide). as per INCB
|